Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Outcomes associated with timing of maintenance treatment for COPD exacerbation.

Dalal AA, Shah MB, D'Souza AO, Dhamane AD, Crater GD.

Am J Manag Care. 2012 Sep 1;18(9):e338-45.

4.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA.

Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1.

5.

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.

Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.

PMID:
19948302
6.

Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.

Dalal AA, Shah M, D'Souza AO, Crater GD.

Respir Med. 2012 Jun;106(6):829-37. doi: 10.1016/j.rmed.2011.11.012. Epub 2012 Mar 17.

7.

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.

Dalal AA, Shah M, D'Souza AO, Chaudhari S, Crater G.

Int J Chron Obstruct Pulmon Dis. 2012;7:11-9. doi: 10.2147/COPD.S27846. Epub 2012 Jan 18.

8.

Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.

Akazawa M, Biddle AK, Stearns SC.

Clin Ther. 2008;30 Spec No:1003-16. doi: 10.1016/j.clinthera.2008.05.020.

PMID:
18640475
9.

Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.

Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM.

Curr Med Res Opin. 2009 Jan;25(1):1-13. doi: 10.1185/03007990802534020 .

PMID:
19210134
10.

Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population.

Dalal AA, Shah M, Lunacsek O, Hanania NA.

COPD. 2011 Aug;8(4):293-9. doi: 10.3109/15412555.2011.586659. Epub 2011 Aug 9.

PMID:
21827298
11.

Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder.

Chen S, Plauschinat CA, Wu N, Fraser K, Boulanger L.

J Med Econ. 2011;14(4):458-62. doi: 10.3111/13696998.2011.588981. Epub 2011 Jun 9.

PMID:
21651427
12.

Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.

Abudagga A, Sun SX, Tan H, Solem CT.

Int J Chron Obstruct Pulmon Dis. 2013;8:175-85. doi: 10.2147/COPD.S40437. Epub 2013 Apr 9.

13.

Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.

Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.

Am J Manag Care. 2008 Jul;14(7):438-48.

14.

Association between incidence of acute exacerbation and medication therapy in patients with COPD.

Suh DC, Lau H, La HO, Choi IS, Geba GP.

Curr Med Res Opin. 2010 Feb;26(2):297-306. doi: 10.1185/03007990903465926.

PMID:
19961283
15.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.

Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

J Med Econ. 2011;14(3):315-23. doi: 10.3111/13696998.2011.576295. Epub 2011 Apr 18.

PMID:
21500975
17.

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.

Moll K, Sun SX, Ellis JJ, Howe A, Amin A.

Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:565-76. doi: 10.2147/COPD.S79025. eCollection 2015.

18.

Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.

AbuDagga A, Sun SX, Tan H, Solem CT.

J Med Econ. 2013;16(3):421-9. doi: 10.3111/13696998.2013.766614. Epub 2013 Jan 29.

PMID:
23336296
19.

Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.

Dalal AA, Shah M, Lunacsek O, Hanania NA.

Respir Med. 2011 Oct;105(10):1516-22. doi: 10.1016/j.rmed.2011.04.005.

20.

Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population.

Simoni-Wastila L, Wei YJ, Qian J, Zuckerman IH, Stuart B, Shaffer T, Dalal AA, Bryant-Comstock L.

Am J Geriatr Pharmacother. 2012 Jun;10(3):201-10. doi: 10.1016/j.amjopharm.2012.04.002. Epub 2012 Apr 21.

PMID:
22521808

Supplemental Content

Support Center